|
1
|
Wang B, Rosano JM, Cheheltani R, Achary MP
and Kiani MF: Towards a targeted multi-drug delivery approach to
improve therapeutic efficacy in breast cancer. Expert Opin Drug
Deliv. 7:1159–1173. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gilman A: The initial clinical trial of
nitrogen mustard. Am J Surg. 105:574–578. 1963. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Papac RJ: Origins of cancer therapy. Yale
J Biol Med. 74:391–398. 2001.
|
|
4
|
Dorr RT and Von Hoff DD: The Cancer
Chemotherapy Handbook. 2nd edition. Appleton & Lange; East
Norwalk, CT: pp. 51994
|
|
5
|
Azzoli CG, Temin S and Giaccone G: 2011
focused update of 2009 American Society of Clinical Oncology
clinical practice guideline update on chemotherapy for stage IV
non-small-cell lung cancer. J Oncol Pract. 8:63–66. 2012.
View Article : Google Scholar
|
|
6
|
Porschen R, Arkenau HT, Kubicka S, Greil
R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A,
Hinke A, Schmiegel W and Schmoll HJ: Phase III study of
capecitabine plus oxaliplatin compared with fluorouracil and
leucovorin plus oxaliplatin in metastatic colorectal cancer: a
final report of the AIO Colorectal Study Group. J Clin Oncol.
25:4217–4223. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Madi A, Fisher D, Wilson RH, Adams RA,
Meade AM, Kenny SL, Nichols LL, Seymour MT, Wasan H, Kaplan R and
Maughan TS: Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU
in advanced colorectal cancer: the MRC COIN trial. Br J Cancer.
107:1037–1043. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hassett MJ, O’Malley AJ, Pakes JR,
Newhouse JP and Earle CC: Frequency and cost of
chemotherapy-related serious adverse effects in a population sample
of women with breast cancer. J Natl Cancer Inst. 98:1108–1117.
2006. View Article : Google Scholar
|
|
9
|
Altena R, Perik PJ, van Veldhuisen DJ, de
Vries EG and Gietema JA: Cardiovascular toxicity caused by cancer
treatment: strategies for early detection. Lancet Oncol.
10:391–399. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Howlader N, Noone A, Krapcho M, Neyman N,
Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z,
Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ and
Cronin KA: SEER Cancer Statistics Review, 1975–2009. Vintage 2009
Populations. National Cancer Institute; Bethesda, MD: 2012
|
|
11
|
Ardizzoni A, Boni L, Tiseo M, Fossella FV,
Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal
P, Mazzanti P, Bisset D and Rosell R; CISCA (CISplatin versus
CArboplatin) Meta-analysis Group. Cisplatin- versus
carboplatin-based chemotherapy in first-line treatment of advanced
non-small-cell lung cancer: an individual patient data
meta-analysis. J Natl Cancer Inst. 99:847–857. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ross JS, Schenkein DP, Pietrusko R, Rolfe
M, Linette GP, Stec J, Stagliano NE, Ginsburg GS, Symmans WF,
Pusztai L and Hortobagyi GN: Targeted therapies for cancer 2004. Am
J Clin Pathol. 122:598–609. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Swaby RF, Sharma CG and Jordan VC: SERMs
for the treatment and prevention of breast cancer. Rev Endocr Metab
Disord. 8:229–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Early Breast Cancer Trialists’
Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal
therapy for early breast cancer on recurrence and 15-year survival:
an overview of the randomised trials. Lancet. 365:1687–1717.
2005.
|
|
15
|
Grandis JR and Sok JC: Signaling through
the epidermal growth factor receptor during the development of
malignancy. Pharmacol Ther. 102:37–46. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dutta PR and Maity A: Cellular responses
to EGFR inhibitors and their relevance to cancer therapy. Cancer
Lett. 254:165–177. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Okamoto I: Epidermal growth factor
receptor in relation to tumor development: EGFR-targeted anticancer
therapy. FEBS J. 277:309–315. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harandi A, Zaidi AS, Stocker AM and Laber
DA: Clinical efficacy and toxicity of anti-EGFR therapy in common
cancers. J Oncol. 2009:5674862009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sequist LV: First-generation epidermal
growth factor receptor tyrosine kinase inhibitors in EGFR mutation:
positive non-small cell lung cancer patients. J Thorac Oncol.
3:143–145. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Douillard JY, Shepherd FA, Hirsh V, et al:
Molecular predictors of outcome with gefitinib and docetaxel in
previously treated non-small-cell lung cancer: data from the
randomized phase III INTEREST trial. J Clin Oncol. 28:744–752.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Folkman J: Tumor angiogenesis: therapeutic
implications. New Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Folkman J: Angiogenesis: an organizing
principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
National Cancer Institute. Angiogenesis
inhibitors. FactSheet. http://www.cancer.gov/cancertopics/factsheet/Therapy/angiogenesis-inhibitors.
Revised October 7, 2011.
|
|
24
|
Heath VL and Bicknell R: Anticancer
strategies involving the vasculature. Nat Rev Clin Oncol.
6:395–404. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ivy SP, Wick JY and Kaufman BM: An
overview of small-molecule inhibitors of VEGFR signaling. Nat Rev
Clin Oncol. 6:569–579. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jayson GC, Hicklin DJ and Ellis LM:
Antiangiogenic therapy - evolving view based on clinical trial
results. Nat Rev Clin Oncol. 9:297–303. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ebos JM and Kerbel RS: Antiangiogenic
therapy: impact on invasion, disease progression, and metastasis.
Nat Rev Clin Oncol. 8:210–221. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Oudard S, Beuselinck B, Decoene J and
Albers P: Sunitinib for the treatment of metastatic renal cell
carcinoma. Cancer Treat Rev. 37:178–184. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, et al:
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bergers G and Hanahan D: Modes of
resistance to anti-angiogenic therapy. Nat Rev Cancer. 8:592–603.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shojaei F: Anti-angiogenesis therapy in
cancer: current challenges and future perspectives. Cancer Lett.
320:130–137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tanne JH: FDA cancels approval for
bevacizumab in advanced breast cancer. BMJ. 343:d76842011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Goulart BH, Clark JW, Pien HH, Roberts TG,
Finkelstein SN and Chabner BA: Trends in the use and role of
biomarkers in phase I oncology trials. Clin Cancer Res.
13:6719–6726. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yarden Y: The EGFR family and its ligands
in human cancer. Signaling mechanisms and therapeutic
opportunities. Eur J Cancer. 37:S3–S8. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Buller RM, Chakrabarti S, Moss B and
Fredrickson T: Cell proliferative response to vaccinia virus is
mediated by VGF. Virology. 164:182–192. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Langhammer S, Koban R, Yue C and Ellerbrok
H: Inhibition of poxvirus spreading by the anti-tumor drug
Gefitinib (Iressa). Antiviral Res. 89:64–70. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ratner L, Fisher A, Jagodzinski LL,
Mitsuya H, Liou RS, Gallo RC and Wong-Staal F: Complete nucleotide
sequences of functional clones of the AIDS virus. AIDS Res Hum
Retroviruses. 3:57–69. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Perelson AS, Neumann AU, Markowitz M,
Leonard JM and Ho DD: HIV-1 dynamics in vivo: virion clearance
rate, infected cell life-span, and viral generation time. Science.
271:1582–1586. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Campbell TB, Schneider K, Wrin T,
Petropoulos CJ and Connick E: Relationship between in vitro human
immunodeficiency virus type 1 replication rate and virus load in
plasma. J Virol. 77:12105–12112. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ho DD, Neumann AU, Perelson AS, Chen W,
Leonard JM and Markowitz M: Rapid turnover of plasma virions and
CD4 lymphocytes in HIV-1 infection. Nature. 373:123–126. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hemelaar J: The origin and diversity of
the HIV-1 pandemic. Trends Mol Med. 18:182–192. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Klein CA: Parallel progression of primary
tumors and metastases. Nat Rev Cancer. 9:302–312. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Greaves M and Maley CC: Clonal evolution
in cancer. Nature. 481:306–313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Merlo LM, Pepper JW, Reid BJ and Maley CC:
Cancer as an evolutionary and ecological process. Nat Rev Cancer.
6:924–935. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Maley CC, Galipeau PC, Finley JC,
Wongsurawat VJ, Li X, Sanchez CA, Paulson TG, Blount PL, Risques
RA, Rabinovitch PS and Reid BJ: Genetic clonal diversity predicts
progression to esophageal adenocarcinoma. Nat Genet. 38:468–473.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pepper J, Findlay CS, Kassen R, Spencer S
and Maley CC: Cancer research meets evolutionary biology. Evol
Appl. 2:62–70. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
González-García I, Solé RV and Costa J:
Metapopulation dynamics and spatial heterogeneity in cancer. Proc
Natl Acad Sci USA. 99:13085–13089. 2002.
|
|
48
|
Staveley-O’Corrol K, Sotomayor E,
Mongomery J, Borrello I, Hwang L, Fein S, Pardoll D and Levitsky H:
Induction of antigen-specific T cell anergy: an early event in the
course of tumor progression. Proc Natl Acad Sci USA. 95:1178–1183.
1998.PubMed/NCBI
|
|
49
|
Finke J, Ferrone S, Frey A, Mufson A and
Ochoa A: Where have all the T cells gone? Mechanisms of immune
evasion by tumors. Immunol Today. 20:158–160. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Levy LS: Retrovirus-induced
immunodeficiency and cancer. Retroviruses and Insights into Cancer.
Dudley J: Springer; New York: pp. 259–283. 2011
|
|
51
|
Dunn GP, Bruce AT, Ikeda H, Old LJ and
Schreiber RD: Cancer immunoediting: from immunosurveillance to
tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zitvogel L, Tesniere A and Kroemer G:
Cancer despite immunosurveillance: immunoselection and
immunosubversion. Nat Rev Immunol. 6:715–727. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Leslie AJ, Pfafferott KJ, Chetty P,
Draenert R, Addo MM, Feeney M, Tang Y, Holmes EC, Allen T, Prado
JG, Altfeld M, Brander C, Dixon C, Ramduth D, Jeena P, Thomas SA,
St John A, Roach TA, Kupfer B, Luzzi G, Edwards A, Taylor G, Lyall
H, Tudor-Williams G, Novelli V, Martinez-Picado J, Kiepiela P,
Walker BD and Goulder PJ: HIV evolution: CTL escape mutation and
reversion after transmission. Nat Med. 10:282–289. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Klenerman P, Wu Y and Phillips R: HIV:
current opinion in escapology. Curr Opin Microbiol. 5:408–413.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang T, Niu G, Kortylewski M, Burdelya L,
Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola
D, Dalton W, Jove R, Pardoll D and Yu H: Regulation of the innate
and adaptive immune responses by Stat-3 signaling in tumor cells.
Nat Med. 10:48–54. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
56
|
Oosterhoff D, Lougheed S, van de Ven R,
Lindenberg J, van Cruijsen H, Hiddingh L, Kroon J, van den Eertwegh
AJ, Hangalapura B, Scheper RJ and de Gruijl TD: Tumor-mediated
inhibition of human dendritic cell differentiation and function is
consistently counteracted by combined p38 MAPK and STAT3
inhibition. Oncoimmunology. 1:649–658. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lee CA, Phillips AN, Elford J, Janossy G,
Griffiths P and Kernoff P: Progression of HIV disease in a
haemophilic cohort followed for 11 years and the effect of
treatment. BMJ. 303:1093–1096. 1991.Erratum in: BMJ 303: 1446,
1991.
|
|
58
|
Hammer SM, Katzenstein DA, Hughes MD,
Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair
JP, Niu M, Hirsch MS and Merigan TC: A trial comparing nucleoside
monotherapy with combination therapy in HIV-infected adults with
CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical
Trials Group Study 175 Study Team. N Engl J Med. 335:1081–1090.
1996. View Article : Google Scholar
|
|
59
|
Hammer SM, Squires KE, Hughes MD, Grimes
JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr,
Deyton LR, Chodakewitz JA and Fischl MA: A controlled trial of two
nucleoside analogues plus indinavir in persons with human
immunodeficiency virus infection and CD4 cell counts of 200 per
cubic millimeter or less. AIDS Clinical Trials Group 320 Study
Team. N Engl J Med. 337:725–733. 1997. View Article : Google Scholar
|
|
60
|
Leung D, Abbenante G and Fairlie DP:
Protease inhibitors: current status and future prospects. J Med
Chem. 43:305–341. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Sterne JA, Hernán MA, Ledergerber B,
Tilling K, Weber R, Sendi P, Rickenbach M, Robins JM and Egger M;
Swiss HIV Cohort Study. Long-term effectiveness of potent
antiretroviral therapy in preventing AIDS and death: a prospective
cohort study. Lancet. 366:378–384. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Saif MW, Katirtzoglou NA and Syrigos KN:
Capecitabine: an overview of the side effects and their management.
Anticancer Drugs. 19:447–464. 2008.PubMed/NCBI
|
|
63
|
Hatziveis K, Tourlakis D, Hountis P,
Kyriazanos I, Sougleri M, Ginopoulos P and Camoutsis C: Effects on
the immune system and toxicity of carboplatin/paclitaxel
combination chemotherapy in patients with stage III–IV ovarian and
non-small cell lung cancer and its role in survival and toxicity. J
BUON. 17:143–148. 2012.PubMed/NCBI
|
|
64
|
Li T, Kung HJ, Mack PC and Gandara DR:
Genotyping and genomic profiling of non-small-cell lung cancer:
implications for current and future therapies. J Clin Oncol.
31:1039–1049. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Cohen MH, Gootenberg J, Keegan P and
Pazdur R: FDA drug approval summary: bevacizumab (Avastin) plus
Carboplatin and Paclitaxel as first-line treatment of
advanced/metastatic recurrent nonsquamous non-small cell lung
cancer. Oncologist. 12:713–718. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Shaw AT, Solomon B and Kenudson MM:
Crizotinib and testing for ALK. J Natl Compr Canc Netw.
9:1335–1341. 2011.PubMed/NCBI
|
|
67
|
Takahashi S: Vascular endothelial growth
factor (VEGF), VEGF receptors and their inhibitors for
antiangiogenic tumor therapy. Biol Pharm Bull. 34:1785–1788. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Doi Y, Yashiro M, Yamada N, Amano R, Noda
S and Hirakawa K: VEGF-A/VEGFR-2 signaling plays an important role
for the motility of pancreas cancer cells. Ann Surg Oncol.
19:2733–2743. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Olsson AK, Dimberg A, Kreuger J and
Claesson-Welsh L: VEGF receptor signalling - in control of vascular
function. Nat Rev Mol Cell Biol. 7:359–371. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Abrams TJ, Murray LJ, Pesenti E, Holway
VW, Colombo T, Lee LB, Cherrington JM and Pryer NK: Preclinical
evaluation of the tyrosine kinase inhibitor SU11248 as a single
agent and in combination with ‘standard of care’ therapeutic agents
for the treatment of breast cancer. Mol Cancer Ther. 2:1011–1021.
2003.
|
|
71
|
Ferrara N, Hillan KJ, Gerber HP and
Novotny W: Discovery and development of bevacizumab, an anti-VEGF
antibody for treating cancer. Nat Rev Drug Discov. 3:391–400. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Burger JA, Stewart DJ, Wald O and Peled A:
Potential of CXCR4 antagonists for the treatment of metastatic lung
cancer. Expert Rev Anticancer Ther. 11:621–630. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Zhao BC, Wang ZJ, Mao WZ, Ma HC, Han JG,
Zhao B and Xu HM: CXCR4/SDF-1 axis is involved in lymph node
metastasis of gastric carcinoma. World J Gastroenterol.
17:2389–23896. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Hou KL, Hao MG, Bo JJ and Wang JH: CXCR7
in tumorigenesis and progression. Chin J Cancer. 29:456–459. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Burger M, Glodek A, Hartmann T,
Schmitt-Gräff A, Silberstein LE, Fujii N, Kipps TJ and Burger JA:
Functional expression of CXCR4 (CD184) on small-cell lung cancer
cells mediates migration, integrin activation, and adhesion to
stromal cells. Oncogene. 22:8093–80101. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Soriano SF, Serrano A, Hernanz-Falcón P,
Martín de Ana A, Monterrubio M, Martinez C, Rodríguez-Frade JM and
Mellado M: Chemokines integrate JAK/STAT and G-protein pathways
during chemotaxis and calcium flux responses. Eur J Immunol.
33:1328–1333. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Kijima T, Maulik G, Ma PC, Tibaldi EV,
Turner RE, Rollins B, Sattler M, Johnson BE and Salgia R:
Regulation of cellular proliferation, cytoskeletal function, and
signal transduction through CXCR4 and c-Kit in small cell lung
cancer cells. Cancer Res. 62:6304–6311. 2002.PubMed/NCBI
|
|
78
|
D’Alterio C, Barbieri A, Portella L, Palma
G, Polimeno M, Riccio A, Ieranò C, Franco R, Scognamiglio G, Bryce
J, Luciano A, Rea D, Arra C and Scala S: Inhibition of stromal
CXCR4 impairs development of lung metastases. Cancer Immunol
Immunother. 61:1713–1720. 2012.PubMed/NCBI
|
|
79
|
Burns JM, Summers BC, Wang Y, Melikian A,
Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ,
Wei K, McMaster BE, Wright K, Howard MC and Schall TJ: A novel
chemokine receptor for SDF-1 and I-TAC involved in cell survival,
cell adhesion, and tumor development. J Exp Med. 203:2201–2213.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Sharma M, Afrin F, Satija N, Tripathi RP
and Gangenahalli GU: Stromal-derived factor-1/CXCR4 signaling:
indispensable role in homing and engraftment of hematopoietic stem
cells in bone marrow. Stem Cells Dev. 20:933–946. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
D’Alterio C, Portella L, Ottaiano A, Rizzo
M, Carteni G, Pignata S, Facchini G, Perdona S, Di Lorenzo G,
Autorino R, Franco R, La Mura A, Nappi O, Castello G and Scala S:
High CXCR4 expression correlates with sunitinib poor response in
metastatic renal cancer. Curr Cancer Drug Targets. 12:693–702.
2012.PubMed/NCBI
|
|
82
|
Zhao HB, Tang CL, Hou YL, Xue LR, Li MQ,
Du MR and Li DJ: CXCL12/CXCR4 axis triggers the activation of EGF
receptor and ERK signaling pathway in CsA-induced proliferation of
human trophoblast cells. PLoS One. 7:e383752012. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Keating GM: Plerixafor: a review of its
use in stem-cell mobilization in patients with lymphoma or multiple
myeloma. Drugs. 71:1623–1647. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Attolico I, Pavone V, Ostuni A, Rossini B,
Musso M, Crescimanno A, Martino M, Iacopino P, Milone G, Tedeschi
P, Coluzzi S, Nuccorini R, Pascale S, Di Nardo E and Olivieri A:
Plerixafor added to chemotherapy plus G-CSF is safe and allows
adequate PBSC collection in predicted poor mobilizer patients with
multiple myeloma or lymphoma. Biol Blood Marrow Transplant.
18:241–249. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Li JK, Yu L, Shen Y, Zhou LS, Wang YC and
Zhang JH: Inhibition of CXCR4 activity with AMD3100 decreases
invasion of human colorectal cancer cells in vitro. World J
Gastroenterol. 14:2308–2313. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Garnier D, Magnus N, D’Asti E, Hashemi M,
Meehan B, Milsom C and Rak J: Genetic pathways linking hemostasis
and cancer. Thromb Res. 129(Suppl 1): S22–S29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Nakanishi M, Sato T, Li Y, Nelson AJ,
Farid M, Michalski J, Kanaji N, Wang X, Basma H, Patil A, Goraya J,
Liu X, Togo S, Toews LM, Holz O, Muller KC, Magnussen H and Rennard
SI: Prostaglandin E2 stimulates the production of vascular
endothelial growth factor through the E-prostanoid-2 receptor in
cultured human lung fibroblasts. Am J Respir Cell Mol Biol.
46:217–223. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Luo H, Chen Z, Jin H, Zhuang M, Wang T, Su
C, Lei Y, Zou J and Zhong B: Cyclooxygenase-2 up-regulates vascular
endothelial growth factor via a protein kinase C pathway in
non-small cell lung cancer. J Exp Clin Cancer Res. 30:62011.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Obermajer N, Muthuswamy R, Odunsi K,
Edwards RP and Kalinski P: PGE(2)-induced CXCL12 production and
CXCR4 expression controls the accumulation of human MDSCs in
ovarian cancer environment. Cancer Res. 71:7463–7470. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Shimada K, Anai S, Marco DA, Fujimoto K
and Konishi N: Cyclooxygenase 2-dependent and independent
activation of Akt through casein kinase 2α contributes to human
bladder cancer cell survival. BMC Urol. 11:82011.PubMed/NCBI
|
|
91
|
Pozzi A, Yan X, Macias-Perez I, Wei S,
Hata AN, Breyer RM, Morrow JD and Capdevila JH: Colon carcinoma
cell growth is associated with prostaglandin E2/EP4 receptor-evoked
ERK activation. J Biol Chem. 279:29797–29804. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Schönthal AH: Exploiting
cyclooxygenase-(in)dependent properties of COX-2 inhibitors for
malignant glioma therapy. Anticancer Agents Med Chem. 10:450–461.
2010.PubMed/NCBI
|
